July 28, 2016 – InvitroCue (ASX:IVQ), has signed a research collaboration program with Yong Loo Lin School of Medicine, National University of Singapore. The program will focus on InvitroCue’s “3D human liver” to model an in vitro system for the study of chronic Hepatitis B infection. If the program delivers promising data and results by …
11 July 2016 – InvitroCue (ASX:IVQ), a leader in advanced bio-analytics, has progressed its technology in modelling multi-organ toxicity by developing a novel assay to detect pancreatic toxicity. The assay is part of a strategic collaboration with InSphero AG (Switzerland), the world’s leading provider of assay-ready 3D microtissues for more predictive drug discovery and development. …
May 16, 2016 – InvitroCue (ASX:IVQ), a leader in advanced bio-analytics, announces today a key initiative on Malaria to identify and evaluate new drug targets to tropical infectious diseases. Following its successful initiative on leishmaniasis, InvitroCue establishes an open and collaborative strategy that involves integrated partnerships and networks between academic infectious diseases institutes and pharmaceutical …
May 12, 2016 – InvitroCue (ASX:IVQ), a leader in advanced bio-analytics, announces today that it is planning to enter the oncology testing market for drugs to provide data points in selected solid tumours. Using its revolutionary 3D cell-based technology and proprietary processes, InvitroCue will be able to culture patient derived cancer cells in its laboratories …
SINGAPORE and RESEARCH TRIANGLE PARK, NORTH CAROLINA USA April 08, 2016 – InvitroCue (ASX:IVQ), the in-vitro cell-based assaying company, and SciKon Innovation Inc. a US-based life sciences company, today announce a strategic technology partnership that will enable InvitroCue to enhance its focus on delivering customer-centric innovation for its high-value biopharmaceutical customers. The agreement will allow …
SINGAPORE April 08, 2016 – InvitroCue (ASX:IVQ), the in vitro cell-based assaying company, today announce the global launch of its proprietary Cellacyl® assay to monitor and screen carboxylated drug compounds for acyl glucuronides in liver-derived cells (hepatocytes), enabling pharmaceutical companies to streamline compound-ranking during the early phases of drug discovery. Cellacyl is a unique in …
Download the InvitroCue Agreement PDF here: Agreement
09 March 2016 – InvitroCue Pte Ltd (“IVQ” Singapore), together with London School of Hygiene & Tropical Medicine (London), recently signed an Agreement under which they started a collaboration using 3D in vitro technologies to establish leishmania spp. infection in vitro models. These technologies, when integrated, could offer a novel model for the in vitro …
SINGAPORE and CHINA – March 05, 2016 – InvitroCue Pte Ltd and InvitroCue Biomedical Service Suzhou, a wholly owned subsidiary, today jointly announced the expansion of a cell-based laboratory facility in Suzhou to enhance the company’s current service offerings, and to meet current and future growth of the drug development in China. The expansion is …
CLEVELAND, OHIO and SINGAPORE – February 01, 2016 – ImageIQ, an innovative Imaging Software and Contract Research Organization supporting preclinical research and clinical trials, announced today an agreement with InvitroCue (“IVQ”), a Singapore-based provider of biomedical quantitative image analytic products and services, to enhance and accelerate preclinical research through the use of cloud-based image analysis …